A Plan on Investigation and Collection of Aricept Safety Information With a Dose Increase on Alzheimer's Disease Patients

CompletedOBSERVATIONAL
Enrollment

2,231

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
Alzheimer's Disease
Interventions
DRUG

Aricept

5 mg Aricept increasing dose to 10 mg Aricept, or 10 mg Aricept increasing dose to 23 mg Aricept

Trial Locations (13)

Unknown

Busan

Chungcheongbuk-do

Chungcheongnam-do

Daegu

Gangwon-do

Gwangju

Gyeonggji-do

Gyeongsangbuk-do

Gyeongsangnam-do

Jeju-do

Jeollabuk-do

Jeollanam-do

Seoul

All Listed Sponsors
lead

Eisai Korea Inc.

INDUSTRY

NCT02158910 - A Plan on Investigation and Collection of Aricept Safety Information With a Dose Increase on Alzheimer's Disease Patients | Biotech Hunter | Biotech Hunter